Trial of Antimycobacterial Therapy in Sarcoidosis

NCT ID: NCT01074554

Last Updated: 2016-12-12

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1/PHASE2
• Total Enrollment: 30 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2010-02-28
• Study Completion Date: 2011-02-28

Brief Summary

Growing research from independent laboratories provide an association between mycobacteria and sarcoidosis. More recent immunologic and molecular studies demonstrate immune responses to mycobacteria virulence factors. The purpose of this study is to assess if administration of anti-mycobacterial drug therapy will aid in resolution of cutaneous sarcoidosis lesions.

Detailed Description

Independent molecular and immunologic investigations strengthen the association between mycobacterial antigens and sarcoidosis pathogenesis. Molecular analysis of sarcoidosis granulomas reveals the presence of Mycobacterium tuberculosis complex (MTB) DNA and proteins that are significantly absent from granulomatous controls. Mycobacterial DNA has been detected in cutaneous sarcoidosis lesions, in addition to systemic immune responses against mycobacterial antigens. Due to the association between sarcoidosis and mycobacterial antigens, we postulated that broad spectrum antimycobacterial therapy could lead to restoration of T cell function and clinical improvement of chronic cutaneous sarcoidosis lesions. We investigated the safety and efficacy of Concomitant Levofloxacin, Ethambutol, Azithromycin, and Rifampin (CLEAR) therapy among chronic cutaneous sarcoidosis subjects, with change in lesion diameter from baseline to completion of 8 weeks of therapy as the primary endpoint; we assessed for decreases in granuloma burden, if granulomas were evident upon histologic examination. Change in modified Sarcoidosis Activity Severity Index (SASI) was the secondary endpoint.

Conditions

Sarcoidosis

Keywords

sarcoidosis; mycobacteria; cutaneous lesions

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: DIAGNOSTIC
• Blinding Strategy: SINGLE

Study Groups

Antibiotic Regimen

The Antibiotic Regimen consists of Levaquin 750 mg loading on day 1, then 500 mg po QD and Ethambutol 15-25 mg/kg for a maximum of 1200mg QD and Azithromycin 500mg on day 1, then 250 mg po QD and Rifampin 5-10 mg/kg for a maximum of 300mg po QD.

All four drugs are given concomitantly.

Group Type: EXPERIMENTAL

Antibiotic Regimen

Intervention Type: DRUG

Levaquin 750 mg loading on day 1, then 500 mg po QD Ethambutol 15-25 mg/kg for a maximum of 1200mg QD Azithromycin 500mg on day 1, then 250 mg po QD Rifampin 5-10 mg/kg for a maximum of 300mg po QD All four drugs are given concomitanly

Placebo Regimen

The placebo regimen consists of Lactose tablets, one for each antibiotic with equivalent pills

Group Type: PLACEBO_COMPARATOR

Placebo Regimen

Intervention Type: DRUG

lactose control tablets; one for each antibiotic with equivalent pills

Interventions

Antibiotic Regimen

Levaquin 750 mg loading on day 1, then 500 mg po QD Ethambutol 15-25 mg/kg for a maximum of 1200mg QD Azithromycin 500mg on day 1, then 250 mg po QD Rifampin 5-10 mg/kg for a maximum of 300mg po QD All four drugs are given concomitanly

Intervention Type: DRUG

Placebo Regimen

lactose control tablets; one for each antibiotic with equivalent pills

Intervention Type: DRUG

Other Intervention Names

Levaquin=Levofloxacin; Ethambutol=Myambutol; Azithromycin=Zithromax; Rifampin=Rifadin; Lactose control tablets

Eligibility Criteria

Inclusion Criteria

1. Patients with sarcoidosis as defined by the ATS/ERS/WASOG statement on sarcoidosis as defined by the clinical presentation consistent with sarcoidosis, biopsy finding granulomas, and no alternative for the cause of the granulomas, such as tuberculosis

2. Patients must have chronic cutaneous skin lesions with or without taking chronic therapy (corticosteroids, methotrexate (max 10mg/week), azathioprine, hydroxychloroquine, cyclophosphamide, minocycline, doxycycline and chloroquine), in which the dose has not been altered in the 2 months prior to starting the study.

3. Subject has a diagnosis of cutaneous sarcoidosis for greater than 6 months with a Sarcoidosis Activity and Severity Index assessment score of at least 4. Diagnosis can be made by either:

• Skin lesions characteristic of sarcoidosis and a biopsy showing granulomas with no evidence of mycobacteria, fungus, or malignancy.
• A biopsy that does not show granulomas, but the patient has characteristic skin lesions and history of clinical features suggesting sarcoidosis (previous biopsy revealing noncaseating granuloma, bilateral hilar adenopathy, erythema nodosum, uveitis, raised ACE level, BAL lymphocytosis (CD4:CD8>3.5), panda/lambda sign on gallium scan)
• Accepted clinical variants include, but are not necessarily limited to the following:

• lupus pernio
• nodular
• subcutaneous
• annular
• angiolupoid
• plaque
• papular
• lichenoid
• psoriasiform
• For purposes of this study "moderate to severe cutaneous sarcoidosis" is defined as the presence of sarcoidal skin lesions with any of the following features:

• At least 5 easily visible facial lesions, or
• Disease which involves > 3% BSA, or
• Disease which confers functional impairment (e.g. nasal or visual field obstruction), or
• Disease which confers significant symptoms of itching and/or pain.

4. If female, subject is either not of childbearing potential, defined as postmenopausal for at least 1 year or surgically sterile (bilateral tubal ligation, bilateral oophorectomy, or hysterectomy), or is using one of the following methods of birth control for the duration of the study and 90 days after study completion:

• condoms, sponge, foams, jellies, diaphragm, or intrauterine device
• contraceptives (oral or parenteral) for three months prior to study drug administration
• a vasectomized sole partner
• Females of childbearing potential must have a negative serum pregnancy test at screening visit.

Exclusion Criteria

1. No consent/inability to obtain consent.

2. Age less than 18 years of age.

3. Inability to obtain biopsy or draw blood.

4. CPK, ALT or AST >5 times upper limit of normal (ULN)

5. Pregnancy or breast feeding.

6. Current use of medications metabolized by rifampin (See Appendix).

7. Allergy to macrolides, quinolones or rifamycins.

8. Visual Impairment as defined by differentiating colors.

9. Family or personal history of long QT syndromes.

10. Patients receiving another interventional investigational drug within the 30 days prior to dosing

11. Use of any investigational medication within the past 28 days prior to study enrollment.

12. Subject has been hospitalized for infection or received IV antibiotics within the previous 2 months prior to baseline.

13. Subject has a history of tuberculosis at anytime or close contact with a person with active tuberculosis within the previous 6 months, or persistent or active infections requiring hospitalization or treatment with IV antibiotics, IV antiretrovirals, or IV antifungals within 30 days of baseline, OR oral antibiotics, antivirals, or antifungals for purpose of treating infection, within 14 days of baseline.

14. Evidence of other active skin diseases or skin infections during screening that may interfere with evaluation of sarcoidosis.

15. Subject has an active infection requiring systemic antibiotics at time of screening

16. Subject has a history of listeriosis, treated or untreated tuberculosis, exposure to individuals with tuberculosis.

17. Subject has a variant of sarcoidosis that is not amenable to study evaluation, in the absence of chronic indurated lesions, such as:

• Acute, "benign" sarcoid associated with erythema nodosum
• Acute iritis
• Ichthyosiform sarcoidosis
• Hypo- or hyperpigmented macular sarcoidosis
• Ulcerative sarcoidosis
• Erythroderma
• Alopecia

18. Patients otherwise unsuitable for participation in the opinion of the investigator

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Vanderbilt University

OTHER

Sponsor Role: lead

Responsible Party

Wonder Drake

Associate Professor of Medicine

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Wonder P Drake, MD

Role: PRINCIPAL_INVESTIGATOR

Vanerbilt University School of Medicine

Locations

Vanderbilt University School of Medicine

Nashville, Tennessee, United States

Countries

United States

References

Drake WP, Oswald-Richter K, Richmond BW, Isom J, Burke VE, Algood H, Braun N, Taylor T, Pandit KV, Aboud C, Yu C, Kaminski N, Boyd AS, King LE. Oral antimycobacterial therapy in chronic cutaneous sarcoidosis: a randomized, single-masked, placebo-controlled study. JAMA Dermatol. 2013 Sep;149(9):1040-9. doi: 10.1001/jamadermatol.2013.4646.

Reference Type: DERIVED

PMID: 23863960 (View on PubMed)

Other Identifiers

091103

Identifier Type: -

Identifier Source: org_study_id